X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs DIVIS LABORATORIES - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA DIVIS LABORATORIES SUN PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 37.6 38.4 98.1% View Chart
P/BV x 4.0 6.2 64.5% View Chart
Dividend Yield % 0.3 0.7 43.6%  

Financials

 SUN PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
DIVIS LABORATORIES
Mar-18
SUN PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs7011,142 61.4%   
Low Rs433533 81.3%   
Sales per share (Unadj.) Rs110.4146.6 75.3%  
Earnings per share (Unadj.) Rs11.033.0 33.2%  
Cash flow per share (Unadj.) Rs17.238.4 44.9%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.41.2 29.5%  
Book value per share (Unadj.) Rs158.8222.8 71.3%  
Shares outstanding (eoy) m2,399.26265.47 903.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.15.7 89.9%   
Avg P/E ratio x51.625.3 203.7%  
P/CF ratio (eoy) x32.921.8 150.9%  
Price / Book Value ratio x3.63.8 95.0%  
Dividend payout %18.230.3 60.2%   
Avg Mkt Cap Rs m1,360,021222,318 611.7%   
No. of employees `00017.810.8 165.3%   
Total wages/salary Rs m53,6714,561 1,176.8%   
Avg. sales/employee Rs Th14,890.93,616.0 411.8%   
Avg. wages/employee Rs Th3,017.1423.8 712.0%   
Avg. net profit/employee Rs Th1,480.6814.9 181.7%   
INCOME DATA
Net Sales Rs m264,89538,915 680.7%  
Other income Rs m8,3881,134 739.4%   
Total revenues Rs m273,28240,049 682.4%   
Gross profit Rs m56,08112,617 444.5%  
Depreciation Rs m14,9981,425 1,052.6%   
Interest Rs m5,17613 38,915.0%   
Profit before tax Rs m44,29512,313 359.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4523,543 238.5%   
Profit after tax Rs m26,3388,770 300.3%  
Gross profit margin %21.232.4 65.3%  
Effective tax rate %19.128.8 66.3%   
Net profit margin %9.922.5 44.1%  
BALANCE SHEET DATA
Current assets Rs m316,35945,351 697.6%   
Current liabilities Rs m198,6436,507 3,052.7%   
Net working cap to sales %44.499.8 44.5%  
Current ratio x1.67.0 22.9%  
Inventory Days Days95127 74.8%  
Debtors Days Days10895 113.2%  
Net fixed assets Rs m213,17821,160 1,007.5%   
Share capital Rs m2,399531 451.9%   
"Free" reserves Rs m378,60658,625 645.8%   
Net worth Rs m381,00659,156 644.1%   
Long term debt Rs m17,7210-   
Total assets Rs m643,02867,832 948.0%  
Interest coverage x9.6926.8 1.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.40.6 71.8%   
Return on assets %4.912.9 37.8%  
Return on equity %6.914.8 46.6%  
Return on capital %10.020.8 48.1%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m40,81632,359 126.1%   
Fx outflow Rs m30,1439,042 333.4%   
Net fx Rs m10,67323,317 45.8%   
CASH FLOW
From Operations Rs m39,0727,759 503.6%  
From Investments Rs m-33,708-4,783 704.7%  
From Financial Activity Rs m-15,393-3,142 490.0%  
Net Cashflow Rs m-7,359-166 4,433.2%  

Share Holding

Indian Promoters % 63.7 52.0 122.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 11.8 43.5%  
FIIs % 23.0 19.0 121.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 17.2 48.3%  
Shareholders   133,026 31,796 418.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   BIOCON LTD  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS